Korro Bio initiated with a Buy at Clear Street

Clear Street analyst Bill Maughan initiated coverage of Korro Bio (KRRO) with a Buy rating and $93 price target The company is developing a pipeline of products using RNA-editing technology, the analyst tells investors in a research note. The firm says Korro’s lead asset KRRO-110’s preclinical data suggest that it is the best-in-class clinical-stage RNA editor for alpha-1 antitrypsin disease.